Litcius/Paper detail

SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses

Chuncong Mo, Xiao Li, Qianying Wu, Ye Fan, Donglan Liu, Yuhui Zhu, Yujie Yang, Xiaohong Liao, Zhichao Zhou, Liling Zhou, Qiuru Li, Qiong Zhang, Wenkuan Liu, Rong Zhou, Xingui Tian

2023Vaccine19 citationsDOIOpen Access PDF

Abstract

New SARS-CoV-2 variants continue to prevail worldwide, and effective vaccines are needed to prevent an epidemic. mRNA vaccines are gradually being applied to the prevention and control of infectious diseases with significant safety and effectiveness. The spike (S) protein of SARS-CoV-2 is the main target of mRNA vaccine design, but the impact of the signal peptide (SP), transmembrane region (TM), and cytoplasmic tail (CT) on mRNA vaccine remains unclear. In this study, we constructed three forms of mRNA vaccines related to the S protein: full-length, deletion of the TM and CT, and simultaneous deletion of the SP, TM and CT, and compared their immunogenicity. Our experimental data show that full-length S protein and deletion of the TM and CT could effectively induce neutralizing antibody production in mice, while S protein without the SP and TM could not. This indicates that the S protein SP is necessary for the design of mRNA vaccine.

Topics & Concepts

ImmunogenicityMessenger RNAVirologySignal peptideAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyBiologyPeptide vaccineTransmembrane proteinCoronavirus disease 2019 (COVID-19)NeutralizationMedicinePeptide sequenceImmunologyGeneEpitopeGeneticsReceptorInfectious disease (medical specialty)PathologyDiseaseSARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene DeliveryViral Infections and Immunology Research
SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses | Litcius